AnaptysBio, Inc. Profile Avatar - Palmy Investing

AnaptysBio, Inc.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-3…

Biotechnology
US, San Diego [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of ANAB's Analysis
CIK: 1370053 CUSIP: 032724106 ISIN: US0327241065 LEI: - UEI: -
Secondary Listings
ANAB has no secondary listings inside our databases.